Amphastar P

Healthcare US AMPH

39.3949USD
-0.0551(0.14%)

Last update at 2024-12-19T18:52:00Z

Day Range

38.8140.26
LowHigh

52 Week Range

36.5665.92
LowHigh

Fundamentals

  • Previous Close 39.45
  • Market Cap2107.41M
  • Volume364572
  • P/E Ratio14.56
  • Dividend Yield-%
  • EBITDA266.61M
  • Revenue TTM723.55M
  • Revenue Per Share TTM14.94
  • Gross Profit TTM 248.86M
  • Diluted EPS TTM3.01

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax 171.36M 116.04M 84.14M 4.64M 60.23M
Minority interest 0.00000M 0.00000M 1.19M -0.30600M -2.43400M
Net income 137.54M 91.39M 62.12M 1.10M 48.94M
Selling general administrative 51.54M 45.06M 51.43M 50.38M 50.28M
Selling and marketing expenses 28.85M 21.53M 17.49M 14.78M 12.83M
Gross profit 351.12M 248.86M 199.74M 143.34M 131.92M
Reconciled depreciation 35.78M 28.74M 26.75M 25.18M 21.12M
Ebit 198.52M 78.76M 85.02M 5.01M -0.03900M
Ebitda 240.29M 107.50M 111.78M 30.19M 21.08M
Depreciation and amortization 41.78M 28.74M 26.75M 25.18M 21.12M
Non operating income net other - 9.21M 14.93M -5.94300M 60.39M
Operating income 196.99M 78.76M 43.13M -14.22600M -0.03900M
Other operating expenses 447.41M 391.49M 367.88M 338.89M 322.40M
Interest expense 27.16M 1.85M 0.89M 0.37M 0.12M
Tax provision 34.45M 23.48M 20.63M 3.54M 13.72M
Interest income 3.74M 1.32M 0.60M 0.64M 1.00M
Net interest income -14.49400M -0.52500M -0.28400M 0.27M 0.88M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 31.83M 23.48M 20.63M 3.54M 13.72M
Total revenue 644.39M 498.99M 437.77M 349.85M 322.36M
Total operating expenses 154.13M 141.36M 129.85M 132.39M 131.96M
Cost of revenue 293.27M 250.13M 238.03M 206.51M 190.43M
Total other income expense net -25.62800M 8.54M 14.25M -6.31700M 60.27M
Discontinued operations - - - - -
Net income from continuing ops 135.29M 91.39M 63.51M 1.10M 46.51M
Net income applicable to common shares - 91.39M 62.12M 1.40M 48.94M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1512.91M 741.99M 671.53M 631.24M 586.97M
Intangible assets 610.08M 34.17M 35.56M 36.67M 37.52M
Earning assets - - - - -
Other current assets 9.58M 7.56M 7.27M 6.78M 9.54M
Total liab 873.49M 213.33M 226.01M 182.51M 159.44M
Total stockholder equity 639.42M 528.66M 445.52M 402.31M 381.37M
Deferred long term liab - - 0.53M 0.74M 0.87M
Other current liab 194.02M 4.57M 9.08M 1.08M 2.04M
Common stock 0.00600M 0.00600M 0.00600M 0.00500M 0.00500M
Capital stock 0.00600M 0.00600M 0.00600M 0.00500M 0.00500M
Retained earnings 409.27M 271.72M 180.34M 117.77M 116.37M
Other liab - 21.93M 22.72M 18.66M 13.72M
Good will 3.22M 3.13M 3.31M 3.94M 3.63M
Other assets - 59.38M 39.06M 50.88M 37.03M
Cash 144.53M 156.10M 126.35M 92.64M 73.69M
Cash and equivalents - - - - -
Total current liabilities 225.41M 94.86M 103.81M 112.20M 90.01M
Current deferred revenue 1.61M - - - -
Net debt 479.11M -53.51600M -21.69000M -25.37200M -7.06000M
Short term debt 4.34M 6.05M 5.18M 15.62M 10.92M
Short long term debt 0.44M 3.05M 2.20M 12.26M 7.74M
Short long term debt total 623.64M 102.58M 104.66M 67.27M 66.62M
Other stockholder equity 238.62M 265.55M 271.94M 288.25M 269.68M
Property plant equipment - 238.27M 244.24M 260.06M 233.86M
Total current assets 489.60M 378.32M 318.12M 279.68M 255.24M
Long term investments 15.21M 2.41M 3.98M - -
Net tangible assets - 491.36M 406.65M 361.69M 340.21M
Short term investments 114.71M 19.66M 10.32M 12.98M 11.68M
Net receivables 114.94M 88.97M 78.93M 66.39M 45.69M
Long term debt 589.58M 72.84M 74.78M 34.19M 39.39M
Inventory 105.83M 103.58M 92.81M 96.83M 110.50M
Accounts payable 25.44M 84.24M 89.55M 95.50M 77.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 46.42M 46.16M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8.47800M -8.62400M -6.76500M -3.72100M -4.68700M
Additional paid in capital - - - - -
Common stock total equity - 0.00600M 0.00600M 0.00500M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - 271.72M 180.34M 117.77M 116.37M
Treasury stock - -189.52400M -150.47900M -121.81200M -97.62700M
Accumulated amortization - - - - -
Non currrent assets other 25.91M 20.86M 16.66M 5.25M 11.16M
Deferred long term asset charges - - - - -
Non current assets total 1023.31M 363.67M 353.41M 351.55M 331.73M
Capital lease obligations 33.63M 26.70M 27.68M 20.82M 19.49M
Long term debt total - 72.84M 74.78M 34.19M 39.39M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -546.29600M -7.79200M 1.40M -1.14600M -8.81500M
Change to liabilities - -0.73600M 3.02M 20.61M -11.72000M
Total cashflows from investing activities - -32.77700M -28.67200M -36.41500M -50.52700M
Net borrowings - -2.18800M 30.36M -0.88000M -3.21100M
Total cash from financing activities 454.09M -26.43900M -37.01800M -2.24600M -3.78300M
Change to operating activities - -5.00800M 0.37M -5.64600M -6.21700M
Net income 137.54M 91.39M 63.30M 1.10M 46.51M
Change in cash -11.80200M 29.75M 32.08M 18.96M -12.65200M
Begin period cash flow 156.33M 126.59M 94.51M 75.55M 88.20M
End period cash flow 144.53M 156.33M 126.59M 94.51M 75.55M
Total cash from operating activities 183.50M 89.18M 97.99M 57.27M 41.76M
Issuance of capital stock - - - 0.00000M 18.30M
Depreciation 41.78M 28.74M 26.75M 25.18M 21.12M
Other cashflows from investing activities - -0.95100M -2.61200M -1.41400M -0.15700M
Dividends paid 454.09M 15.66M 15.93M 23.16M -
Change to inventory -1.72400M -11.74600M 1.26M 15.30M -41.10300M
Change to account receivables -26.08600M -10.13200M -14.92100M -20.16000M 6.70M
Sale purchase of stock -58.14400M -39.90900M -28.87300M -24.42500M -22.29100M
Other cashflows from financing activities -14.10500M 15.25M -40.24400M 23.06M 6.99M
Change to netincome - 2.73M 8.04M 20.58M 22.87M
Capital expenditures 38.17M 24.03M 27.46M 33.85M 41.55M
Change receivables - -10.13200M -14.92100M -20.16000M 6.70M
Cash flows other operating - -7.55900M 13.81M -1.68000M 0.40M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 29.96M 32.30M 18.61M -12.54800M
Change in working capital -24.20900M -32.17700M -1.92400M 9.13M -51.74700M
Stock based compensation 20.24M 17.86M 18.69M 20.50M 17.30M
Other non cash items 20.73M -0.87800M -13.03100M 0.24M 1.04M
Free cash flow 145.34M 65.15M 70.54M 23.41M 0.21M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMPH
Amphastar P
-0.0551 0.14% 39.39 14.56 - 2.91 2.89 3.43 8.98
ZTS
Zoetis Inc
-2.975 1.78% 164.03 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.12 0.42% 28.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-1.925 1.33% 142.50 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.07 0.53% 13.04 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Amphastar P

11570 6th Street, Rancho Cucamonga, CA, United States, 91730

Key Executives

Name Title Year Born
Dr. Ziping Luo Ph.D. Chairman, Chief Scientist & COO 1950
Dr. Yongfeng Zhang Ph.D. Co-Founder, Pres, CEO, Chief Scientific Officer & Director 1947
Mr. William J. Peters M.B.A. CFO, Exec. VP of Fin., Treasurer & Director 1968
Mr. Jacob Liawatidewi M.B.A. Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director 1974
Mr. Rong Zhou M.S. Exec. VP of Production Center 1959
Dan Dischner M.B.A. VP of HR & Corp. Communication NA
Tony Marrs M.B.A., M.P.H. Sr. VP of Regulatory Affairs & Clinical Operations NA
Mr. Peter Langosh VP of Operational Improvement and VP of Internal Audit 1953
Dr. Ziping Luo Ph.D. Chairman of the Board, Chief Scientist & COO 1950
Dr. Yongfeng Zhang Ph.D. Co-Founder, President, CEO, Chief Scientific Officer & Director 1947

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.